MO · 10-Q · 2026Q3

ALTRIA GROUP, INC.

Filed 2026-10-29 · Consumer · View original filing on EDGAR

Ranked Events

• Oral Tobacco Revenue and MarginsImportance 72 · Surprise 58
  For the nine months ended September 30, 2026, oral tobacco net revenues fell 1.2% to $2.070 billion, as a $140 million decline from shipment volume was partly offset by $121 million from higher pricing, including…
• Dividends and Capital ReturnsImportance 69 · Surprise 50
  Altria paid $5.330 billion in dividends during the first nine months of 2026, up 3.0% from $5.175 billion in the prior-year period. In August 2026, the Board increased the quarterly dividend 4.7%, from $1.06 to $1.11…
• Settlement and FDA PaymentsImportance 66 · Surprise 40
  Altria estimated average charges to cost of sales of $3.0 billion annually for the next three years for State Settlement Agreement payments and FDA user fees, based on current agreements and estimates. Payments for…
• State Tobacco RestrictionsImportance 59 · Surprise 42
  As of October 26, 2026, California, Massachusetts, New Jersey, New York, Rhode Island, Utah and the District of Columbia had enacted flavor restrictions affecting tobacco products; California’s law covers most flavored…
• Excise Tax TrendsImportance 54 · Surprise 40
  Excise taxes on products declined 10.8% to $2,116 million for the nine months ended September 30, 2026, from $2,373 million in the prior-year period. For the third quarter, excise taxes declined 15.8%, a $130 million…
• Operating Income and MarginsImportance 54 · Surprise 40
  For the nine months ended September 30, 2026, operating income increased 14.0% to $9,405 million from $8,248 million, primarily because OCI was higher and the prior-year comparison included an $873 million non-cash…
• E-Vapor Goodwill ImpairmentImportance 52 · Surprise 42
  Altria recorded a non-cash, pre-tax impairment charge of $873 million for the nine months ended September 30, 2025 to reduce the e-vapor reporting unit’s goodwill to estimated fair value. The impairment followed the…
• Net Income and EPS PerformanceImportance 52 · Surprise 30
  For the nine months ended September 30, 2026, reported net earnings attributable to Altria rose 20.1% to $6,999 million from $5,830 million, and diluted EPS increased 21.2% to $4.18 from $3.45. Adjusted net earnings…
• Oral Tobacco Demand WeaknessImportance 49 · Surprise 32
  Altria’s oral tobacco products segment domestic shipment volume fell 5.4% in the first nine months of 2026, or an estimated 5% after adjusting for trade inventory movements, as retail share losses and inventory…
• Liquidity and Debt PositionImportance 49 · Surprise 32
  At September 30, 2026, Altria held $2.7 billion in cash and cash equivalents and had up to $3.0 billion available under its senior unsecured revolving credit agreement; the company reported compliance with the…
• Operating Cash Flow TrendsImportance 42 · Surprise 14
  Net cash provided by operating activities increased to $6.151 billion in the first nine months of 2026 from $6.019 billion in the comparable 2025 period. The increase primarily reflected lower State Settlement…
• Revenue Performance and MixImportance 42 · Surprise 14
  For the nine months ended September 30, 2026, Smokeable Products net revenues were $13.532 billion, up $465 million (3.6%), while reported OCI increased $327 million (3.9%) to $8.668 billion and adjusted OCI rose $345…
• Equity Investment IncomeImportance 41 · Surprise 48
  For the nine months ended September 30, 2026, income or losses from investments in equity securities improved by $89 million, or 22.4%, primarily because of higher income from Altria’s ABI investment. In the third…
• Graphic Warning Label LitigationImportance 34 · Surprise 42
  The FDA’s March 2020 rule requires 11 graphic cigarette warnings, but its enforcement has been blocked or delayed through litigation. In August 2026, the U.S. Court of Appeals for the Fifth Circuit affirmed a…
• FDA Tobacco Product RegulationImportance 34 · Surprise 42
  In May 2026, the FDA issued guidance on enforcement for certain e-vapor and oral nicotine pouch products with pending PMTAs, generally deprioritizing enforcement for specified products undergoing scientific review or…
• FDA PMTA Review LitigationImportance 34 · Surprise 42
  In September 2026, Helix, NJOY and certain trade partners sued the FDA in the U.S. District Court for the Northern District of Texas, alleging that the agency routinely fails to issue marketing orders within the…
• Cigarette Pricing ActionsImportance 32 · Surprise 24
  PM USA implemented multiple cigarette list-price increases in 2026, including increases effective January 18, April 12 and July 19, generally raising Marlboro (excluding Mainline Menthol and 72s Menthol) and L&M by…
• FDA Tobacco Product StandardsImportance 31 · Surprise 24
  In January 2025, the FDA proposed a nicotine cap for cigarettes and certain combustible tobacco products, including little cigars, cigarillos and most large cigars; the comment period closed in September 2025, and the…
• Oral Nicotine Pouch GrowthImportance 31 · Surprise 32
  The U.S. nicotine pouch category expanded to 59.8% of the U.S. oral tobacco category in the first nine months of 2026, up 7.6 share points, while total oral tobacco category industry volume grew an estimated 5.5% over…
• Tobacco Excise Tax PressureImportance 26 · Surprise 24
  U.S. tobacco products face substantial excise taxes, and the weighted-average state cigarette tax rose from $0.36 per pack at the end of 1998 to $2.02 as of October 26, 2026; Utah enacted a cigarette tax increase in…

Revenue by Product (in millions)